Want to see AMLX full AI Analyst Report?
Total Valuation
Amylyx Pharmaceuticals Inc has a market cap or net worth of $3.64B. The enterprise value is $1.75B.
Market Cap$3.64B
Enterprise Value$1.75B
Share Statistics
Amylyx Pharmaceuticals Inc has 125,513,050 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding125,513,050
Owned by Insiders7.25%
Owned by Institutions0.04%
Financial Efficiency
Amylyx Pharmaceuticals Inc’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -49.26%.
Return on Equity (ROE)-0.47
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)-49.26%
Return on Capital Employed (ROCE)-0.49
Revenue Per Employee0.00
Profits Per Employee-1.06M
Employee Count136
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Amylyx Pharmaceuticals Inc is ―. Amylyx Pharmaceuticals Inc’s PEG ratio is 0.12.
PE Ratio―
PS Ratio0.00
PB Ratio3.74
Price to FCF-9.25
Price to Operating Cash Flow-25.10
PEG Ratio0.12
Income Statement
In the last 12 months, Amylyx Pharmaceuticals Inc had revenue of 0.00 and earned -144.74M in profits. Earnings per share was -1.53.
Revenue0.00
Gross Profit-525.00K
Operating Income-153.29M
Pretax Income-144.69M
Net Income-144.74M
EBITDA-144.16M
Earnings Per Share (EPS)-1.53
Cash Flow
In the last 12 months, operating cash flow was -126.58M and capital expenditures -140.00K, giving a free cash flow of -126.72M billion.
Operating Cash Flow-126.58M
Free Cash Flow-126.72M
Free Cash Flow per Share-1.01
Dividends & Yields
Amylyx Pharmaceuticals Inc pays an annual dividend of $0.42, resulting in a dividend yield of 5.64%
Dividend Per Share$0.42
Dividend Yield5.64%
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.20
52-Week Price Change99.65%
50-Day Moving Average31.11
200-Day Moving Average19.61
Relative Strength Index (RSI)48.96
Average Volume (3m)1.43M
Important Dates
Amylyx Pharmaceuticals Inc upcoming earnings date is Nov 5, 2026, After Close (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Amylyx Pharmaceuticals Inc as a current ratio of 14.27, with Debt / Equity ratio of 2.20%
Current Ratio14.27
Quick Ratio14.27
Debt to Market Cap<0.01
Net Debt to EBITDA1.53
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Amylyx Pharmaceuticals Inc has paid 46.00K in taxes.
Income Tax46.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Amylyx Pharmaceuticals Inc EV to EBITDA ratio is -6.39, with an EV/FCF ratio of -7.46.
EV to Sales0.00
EV to EBITDA-6.39
EV to Free Cash Flow-7.46
EV to Operating Cash Flow-7.47
Balance Sheet
Amylyx Pharmaceuticals Inc has $250.76M in cash and marketable securities with $5.25M in debt, giving a net cash position of $245.50M billion.
Cash & Marketable Securities$250.76M
Total Debt$5.25M
Net Cash$245.50M
Net Cash Per Share$1.96
Tangible Book Value Per Share$3.23
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Amylyx Pharmaceuticals Inc is $46.63, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$46.63
Price Target Upside24.47% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast42.67%